Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Percutaneous BCG Vaccination Prior to Intravesical BCG in NMIBC
NCT02326168Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Oct 2013
- Primary completion
- Oct 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bcg vaccine in Non-muscle-invasive bladder cancer (NMIBC), sponsored by UT Health San Antonio. Primary endpoint: BCG response at 3 months. Started Oct 2013; status: completed.
02
Drugs
bcg vaccine
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02326168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326168.